CN114903890A - 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 - Google Patents

通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Download PDF

Info

Publication number
CN114903890A
CN114903890A CN202210697024.1A CN202210697024A CN114903890A CN 114903890 A CN114903890 A CN 114903890A CN 202210697024 A CN202210697024 A CN 202210697024A CN 114903890 A CN114903890 A CN 114903890A
Authority
CN
China
Prior art keywords
cancer
folate receptor
cells
mdscs
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210697024.1A
Other languages
English (en)
Chinese (zh)
Inventor
P.S.罗
B.王
C.P.利蒙
Y.J.卢
L.W.惠勒二世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Publication of CN114903890A publication Critical patent/CN114903890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202210697024.1A 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Pending CN114903890A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells
CN201780046536.9A CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780046536.9A Division CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN114903890A true CN114903890A (zh) 2022-08-16

Family

ID=60412652

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210697024.1A Pending CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN201780046536.9A Pending CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780046536.9A Pending CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Country Status (8)

Country Link
US (2) US20190216935A1 (enExample)
EP (1) EP3463367A4 (enExample)
JP (1) JP7278777B2 (enExample)
KR (1) KR102489277B1 (enExample)
CN (2) CN114903890A (enExample)
AU (1) AU2017271550B2 (enExample)
IL (1) IL263059B2 (enExample)
WO (1) WO2017205661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763943A (zh) * 2018-08-07 2023-09-19 普渡研究基金会 使car t细胞恢复活力
CN120381528A (zh) * 2019-07-08 2025-07-29 普渡研究基金会 用于治疗和预防纤维化疾病状态和癌症的化合物和方法
CA3184740A1 (en) * 2020-07-08 2022-01-13 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
AU2023232693A1 (en) 2022-03-08 2024-09-19 Connext Co.,Ltd. Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893778A (zh) * 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
WO2011116299A2 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
CN109517897A (zh) * 2011-04-28 2019-03-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
US9550992B2 (en) * 2011-12-02 2017-01-24 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN113620958A (zh) * 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
CN107847609A (zh) * 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GERRIT JANSEN等: "Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer", 《PTERIDINES》, vol. 26, no. 2, pages 157 - 53 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Also Published As

Publication number Publication date
KR102489277B1 (ko) 2023-01-16
IL263059B2 (en) 2025-02-01
RU2018145750A3 (enExample) 2020-07-30
CA3025309A1 (en) 2017-11-30
IL263059B1 (en) 2024-10-01
KR20190021261A (ko) 2019-03-05
AU2017271550A1 (en) 2018-12-06
CN109475558A (zh) 2019-03-15
AU2017271550B2 (en) 2023-11-02
EP3463367A1 (en) 2019-04-10
EP3463367A4 (en) 2020-01-29
US20190216935A1 (en) 2019-07-18
JP2019519524A (ja) 2019-07-11
WO2017205661A1 (en) 2017-11-30
US20210170035A1 (en) 2021-06-10
RU2018145750A (ru) 2020-06-25
IL263059A (en) 2018-12-31
BR112018074119A2 (pt) 2019-03-06
NZ748427A (en) 2025-05-30
JP7278777B2 (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
CN105899491B (zh) 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
US20210170035A1 (en) Method of treating cancer by targeting myeloid-derived suppressor cells
JP6889101B2 (ja) グルタミナーゼ阻害剤の結晶形態
WO2019192454A9 (zh) 新型小分子免疫激动剂和免疫靶向化合物及其应用
JP2024516371A (ja) Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
AU2018258687B2 (en) Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
CN102215844A (zh) 抗叶酸剂的叶酸受体结合轭合物
JP2010531363A (ja) 親水性スペーサーリンカーを含有する結合体
TW200528111A (en) Pyrido-and pyrimidopyrimidine derivatives
US20140171433A1 (en) Multiple myeloma treatment
TW201808345A (zh) 聚乙二醇化卡非佐米化合物
TW201801751A (zh) 靶向構建體及其製劑
US20200038514A1 (en) Folate conjugate for use in targeting tumor associated macrophages
RU2776899C2 (ru) Способ лечения рака нацеливанием на супрессорные клетки миелоидного происхождения
JP2022539804A (ja) 線維性疾患状態およびがんの治療および予防のための化合物ならびに方法
CA3025309C (en) Method of treating cancer by targeting myeloid-derived suppressor cells
KR20230128509A (ko) 암 치료에서 조작된 세포 요법의 향상을 위한 방법
US10683305B2 (en) Deuterated OTX-015
CN117085144A (zh) 配体药物偶联物及其应用
BR112018074119B1 (pt) Uso de compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante, e composição farmacêutica
CN110678204A (zh) 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
CA3181254A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
HK40096682A (zh) 治疗疾病和病症的方法
OA16774A (en) Multiple myeloma treatment.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220816